CTNNB1 and endometrial carcinoma: A systematic review of fifteen observational studies with 1158 endometrial carcinomas showed that the nuclear expression of β-catenin is an accurate immunohistochemical surrogate of CTNNB1 exon 3 mutations and thus might be considered in the endometrial cancer risk stratification [30].